Comprehensive mutational profiling in advanced systemic mastocytosis. - Wikidata - awgldk - TriplyDB

Comprehensive mutational profiling in advanced systemic mastocytosis.

Comprehensive mutational profiling in advanced systemic mastocytosis.

http://www.wikidata.org/entity/Q46716443

about

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients.Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Mast cell activation syndrome as a significant comorbidity in sickle cell disease.Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.The serum tryptase test: an emerging robust biomarker in clinical hematology.Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.Utility of hydroxyurea in mast cell activation syndrome.The genetic basis of myelodysplasia and its clinical relevance Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.Primary mast cell disorders in children.Splicing factor mutations and cancer.Posttranslational modifications of RUNX1 as potential anticancer targets.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.The transcriptional program, functional heterogeneity, and clinical targeting of mast cells.Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.Targeted Treatment Options in Mastocytosis.Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.Case Report: Unusual Manifestation of KIT Negative Systemic Mastocytosis.Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.The spleen microenvironment influences disease transformation in a mouse model of KITD816V-dependent myeloproliferative neoplasm.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

P2860

Q26830207-E8474B80-8DC6-48AA-8AAD-B44578F99AB0 Q27026581-D47309C5-7CC7-4F74-A21C-7E0D4C4C875D Q33423072-7992DA70-899E-4468-8C1C-CB2810E6A283 Q33431360-6A21CF22-A7A6-4BB7-A85F-EE86717A1907 Q33433126-02EA639F-5999-48D3-BE53-36DB340F98B5 Q34137971-47FAD46F-FA80-4A75-84B7-8D2D75B99213 Q34478126-AF40BDDF-C419-4DEB-853B-541EC119838A Q34552564-D81689C1-FBD7-4736-8A4C-FF61D7049177 Q34564293-18B8670B-458F-4CDD-A8F7-067A5F804B1D Q35040226-C7300F59-4CD9-4513-AA76-5E717BD42D67 Q35610140-CC908C72-8946-4D87-A6FE-DE092B315C5D Q36154674-294AD5E9-B558-4393-B432-528D44CA3868 Q36210845-FEFF6041-4292-4B21-85BC-E14E5BABD604 Q36406996-A578542E-B359-40E4-A816-19C888B00D93 Q36977300-C0D19748-1733-4104-A606-2A7A56173051 Q36977305-F4484F13-FDE9-43D7-8089-6FE24B09B709 Q37354739-88DD5A67-3476-414D-81EF-C3F71C51674C Q37365376-5FD6C39B-F273-4A79-BD64-4CC2E8264A2C Q37390236-9ECA47AE-6657-49A2-BC19-D47CC59384CE Q37706037-5EF0F2C0-9031-4D34-8BD8-9F944D16D244 Q38154827-3BD85124-4333-4532-A840-633D06B7297E Q38187632-EA1BA6B7-0A35-4651-AB35-9053DC563E10 Q38255068-868B738D-FF7A-40B2-9677-7F41AD3C3870 Q38370943-2C6B3EF5-9FC7-4FA1-B095-07E7EF0DC416 Q38393275-A312C927-F684-46BA-9611-99BC3D31A4C8 Q38582624-4B64EE6A-D583-46FE-93B7-94A30761C9A7 Q38642037-D155F37B-6F23-4B7F-8123-D6A36805F3DE Q38661465-F5A63A34-3F69-4E19-8351-89CBD75CE11A Q38698612-55E21B5E-E13F-4B3B-9007-EA5DF1DE91A1 Q38777126-C7740E87-62FC-4564-A23F-B810A31B73E4 Q38866094-E59BCAA2-19A9-4221-9891-6DE6AF9072EF Q39601719-490F9C9A-5CC9-42AA-A3AF-997F57104A9E Q39743763-D8FBC02C-EB61-4C2C-AB56-89838DAE7E4E Q41061871-BBFAEE2D-0726-4775-8E1A-7B763943EF8A Q41225286-CAB9A8BA-72DE-4627-A9B8-B27CC6DEC484 Q41533457-56F4C200-4B33-4C71-B763-60E38F194A02 Q41612115-B291E768-FE9C-4CE6-ABBA-53B67F0F8448 Q42234623-4814CAF5-FCAF-43EA-96A2-A3893E5D097A Q42327796-7541304A-E7FC-4FB8-B8AB-70521CE3E4CA Q42376734-F2836A46-C69D-4585-9F64-38E30659BCE6

P2860

Comprehensive mutational profiling in advanced systemic mastocytosis.

http://www.wikidata.org/entity/Q46716443

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Comprehensive mutational profiling in advanced systemic mastocytosis.

@en

Comprehensive mutational profiling in advanced systemic mastocytosis.

@nl

type

label

Comprehensive mutational profiling in advanced systemic mastocytosis.

@en

Comprehensive mutational profiling in advanced systemic mastocytosis.

@nl

prefLabel

Comprehensive mutational profiling in advanced systemic mastocytosis.

@en

Comprehensive mutational profiling in advanced systemic mastocytosis.

@nl

P1433

Q46716443-F110D92F-F871-4BAF-AC72-C3AB16301C68

P1476

Q46716443-736E462B-DA55-4B5D-AEFE-5FDAFEFBB0CE

P2093

Q46716443-1701AEFF-34D7-445D-BADC-5C875E89B0F1

Q46716443-18E72F2C-15D5-4D35-92EE-60E809D55794

Q46716443-3D9ECA42-E16C-441B-BD40-9D713E4EB9B9

Q46716443-5A9ADB6B-64E2-4388-9016-96B0D484A583

Q46716443-5D9B30E0-ABBF-47ED-A014-88BCFCD398AA

Q46716443-83D15FD5-B070-458E-A3F5-C84F76C39ACF

Q46716443-B632D1B6-B997-4402-A824-4F059FB7B940

Q46716443-B81608F9-1C56-4AF9-873F-16982559BD4E

Q46716443-BB239377-F853-43E4-9061-DF2873A14C3C

Q46716443-C6B88C0B-44B6-42E9-A2B7-CAFEB367B7EF

P304

Q46716443-F4752D80-7D7A-454A-86D9-1E734F1BF69E

P31

Q46716443-A34E5964-3427-4B95-A80E-ED0BA9D251AD

P356

Q46716443-2BEF8E8D-8876-4F59-84E9-BAA796C6325A

P407

Q46716443-7C1253E2-3413-4E09-A683-65B619D45EAD

P433

Q46716443-7243F70B-66B9-4BF5-A459-9CCE67E84360

P478

Q46716443-7C70E4A9-7E7B-43C8-92EA-2689530C9A6E

P50

Q46716443-2F9C3D5B-FB09-4297-875B-404061529CEB

Q46716443-410F010E-22A6-4396-A33E-B087B5E4A335

Q46716443-4ABE9821-A054-4922-9C99-D1862EFD4BE6

Q46716443-56D9F6DD-1158-4F0C-98AC-824D1C0DF802

Q46716443-73DFAAB5-87A9-4C81-8807-7DBD84C5DED1

Q46716443-EB39EE0B-4DD5-4F2A-809D-9E2622502D3E

Q46716443-F4F97663-7692-486A-8C6F-CAE12F8C5D14

P577

Q46716443-52B735B4-1EF5-416F-9A5A-E2313C1D40EC

P5875

Q46716443-4F8DD267-5C35-464B-BBDA-BFED742E22B7

P698

Q46716443-25AD0B4C-4BFB-4E36-B032-69FF867F5D72

P356

BLOOD-2013-04-496448

P1433

P1476

Comprehensive mutational profiling in advanced systemic mastocytosis.

@en

P2093

Alexander Kohlmann

http://www.w3.org/2001/XMLSchema#string

Andreas Reiter

http://www.w3.org/2001/XMLSchema#string

Christoph Walz

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Horny

http://www.w3.org/2001/XMLSchema#string

Juliana Schwaab

http://www.w3.org/2001/XMLSchema#string

Karl Sotlar

http://www.w3.org/2001/XMLSchema#string

Markus Pfirrmann

http://www.w3.org/2001/XMLSchema#string

Martina Teichmann

http://www.w3.org/2001/XMLSchema#string

Mohamad Jawhar

http://www.w3.org/2001/XMLSchema#string

Peter Valent

http://www.w3.org/2001/XMLSchema#string

P304

2460-2466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-04-496448

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Torsten Haferlach

Manja Meggendorfer

Georgia Metzgeroth

Susanne Schnittger

P577

2013-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255985782

http://www.w3.org/2001/XMLSchema#string

P698

23958953

http://www.w3.org/2001/XMLSchema#string